DBV Technologies | DBVT - Loan Capital


DBV Technologies reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
BioCryst Pharmaceuticals USD 194.37M 48.43M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
DBV Technologies USD 0 0 Mar/2025
Esperion Therapeutics USD 262.48M 235.95M Jun/2024
Galectin Therapeutics USD 93.42M 9.08M Jun/2024
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
Insmed USD 540.96M 1.24M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
United Therapeutics USD 100M 100M Jun/2024